Tag: Docetaxel

Decipher score is predictive for docetaxel-benefit in mestastatic prostate cancer

Presented By
Dr Emily Grist, University College London, UK
Conference
ESMO 2024
Type
Peer-reviewed article

4 November 2024 11:33

Adding docetaxel to standard-of-care does not improve outcomes in gastric cancer

Presented By
Dr Anant Ramaswamy, Tata Memorial Centre, India
Trial
Phase 3, DOC-GC
Conference
ASCO GI 2024
Type
News article

13 February 2024 14:37

Selective KRASG12C inhibitor sotorasib demonstrates superior PFS and ORR compared to docetaxel in previously treated patients with NSCLC

Presented By
Dr Melissa Johnson, Sarah Cannon Research Institute, TN, USA
Trial
Phase 3, CodeBreaK 200
Conference
ESMO 2022
Type
Peer-reviewed article

16 November 2022 18:14

New standard-of-care for cisplatin-ineligible locally advanced head and neck squamous cell carcinoma

Presented By
Prof. Vanita Noronha, Tata Memorial Hospital, India
Conference
ASCO 2022
Type
Peer-reviewed article

5 August 2022 15:35

ASCO 2022 Highlights Podcast

Presented By
Dr Robert van den Heuvel, Medicom
Conference
ASCO 2022

21 June 2022 09:38

Addition of abiraterone to ADT/docetaxel does not increase bone loss

Presented By
Dr Guilhem Roubaud, Institut Bergonié, France
Trial
Phase 3, PEACE-1
Conference
ASCO GU 2022
Type
Peer-reviewed article

8 April 2022 11:21

DCF outperforms standard-of-care for locally advanced oesophageal cancer

Presented By
Dr Ken Kato, National Cancer Center Hospital, Japan
Trial
Phase 3, JCOG1109, NExT
Conference
ASCO GI 2022
Type
Peer-reviewed article

21 March 2022 11:13

ASCO GI 2022 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom
Conference
ASCO GI 2022

8 February 2022 12:37

Concurrent taxane plus anthracycline most beneficial in reducing risk of breast cancer

Presented By
Dr Jeremy Braybrooke, University Hospitals Bristol NHS Foundation Trust, UK
Conference
SABCS 2021
Type
Peer-reviewed article

31 January 2022 16:44

Both men with high-risk non-metastatic prostate cancer and men with metastatic prostate cancer benefit from intensified hormone treatment

Trial
Phase 3, PEACE-1, STAMPEDE, ARCHES
Conference
ESMO 2021
Type
Peer-reviewed article

19 November 2021 09:27

Radiographic PFS benefit of adding abiraterone to ADT and docetaxel in mCSPC

Presented By
Prof. Karim Fizazi, University of Paris-Saclay, Villejuif, France
Trial
Phase 3, PEACE-1
Conference
EAU 2021
Type
Peer-reviewed article

31 August 2021 12:15

177Lu-PSMA-617: A new class of effective therapy

Presented By
Prof. Johann de Bono; Prof. Michael Hofman
Trial
VISION, TheraP
Conference
EAU 2021
Type
Peer-reviewed article

31 August 2021 12:15

Perioperative chemotherapy and neoadjuvant multimodality therapy appear equally effective

Presented By
Prof. John Reynolds, Trinity St James Cancer Institute, Ireland
Trial
Phase 3, Neo-AEGIS
Conference
ASCO 2021
Type
Peer-reviewed article

12 August 2021 13:18

Lu177 as a promising new therapy for metastatic prostate cancer

Presented By
Dr Michael Hofman, Peter MacCallum Cancer Centre, Australia
Trial
Phase 2, TheraP
Conference
ASCO GU 2021
Type
Peer-reviewed article

24 March 2021 14:49

Neoadjuvant chemotherapy does not increase perioperative complications in thoracic oesophageal cancer

Presented By
Prof. Kazuo Koyanagi, National Cancer Center, Japan
Trial
Phase 3, JCOG 1109
Conference
ASCO GI 2021
Type
Peer-reviewed article

12 March 2021 11:42

Adding docetaxel to adjuvant S-1 reduces gastric cancer relapse

Presented By
Prof. Kazuhiro Yoshida, Gifu University, Japan
Trial
Phase 2, JACCRO GC-07
Conference
ASCO GI 2021
Type
Peer-reviewed article

12 March 2021 11:38

Docetaxel + hormonal therapy: improved prostate cancer PFS

Presented By
Dr Andreas Josefsson , Sahlgrenska University Hospital, Sweden
Trial
Phase 3, SPCG-14
Conference
EAU 2020
Type
Peer-reviewed article

21 August 2020 14:34

Understanding MIBC biology for novel treatment options

Presented By
Prof. Yohann Loriot, Université Paris-Saclay, France
Trial
BLC2001; THOR; EV-301; EV-302; TROPHY-U-01; RANGE
Conference
EAU 2020
Type
Peer-reviewed article

20 August 2020 12:36

Sensory peripheral neuropathy after taxane treatment is not uncommon

Conference
SABCS 2019
Type
Peer-reviewed article

13 February 2020 21:50

No added benefit for doxorubicin + docetaxel vs doxorubicin + cyclophosphamide

Conference
SABCS 2019
Type
Peer-reviewed article

13 February 2020 12:51

Five-fold increase of OS at 5 years with nivolumab vs docetaxel

Presented By
Prof. Scott Gettinger, Yale Cancer Center, USA
Trial
CheckMate 017, CheckMate 057
Conference
WCLC 2019
Type
Peer-reviewed article

8 November 2019 23:00

Avelumab vs docetaxel for previously treated advanced non-small-cell lung cancer

Trial
Phase 3, JAVELIN Lung 200
Conference
WCLC 2018
Type
Peer-reviewed article

21 November 2018 22:46
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com